{"organizations": [], "uuid": "160bf6726f7862d3ac123f8b917191913d4becd0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "finance.yahoo.com", "main_image": "http://l2.yimg.com/bt/api/res/1.2/SqgllMdJ2iT1FiDTGXXfcw--/YXBwaWQ9eW5ld3NfbGVnbztpbD1wbGFuZTtxPTc1O3c9NjAw/http://media.zenfs.com/en-US/video/video.pd2upload.com/video.yahoofinance.com@6d4ff765-90cc-3c9a-bd25-aa952c5d29ea_FULL.jpg", "site_section": "http://finance.yahoo.com/rss/headline?s=COTY", "section_title": "Yahoo! Finance: COTY News", "url": "http://finance.yahoo.com/news/inplay-briefing-com-055139997.html", "country": "US", "title": "InPlay from Briefing.com", "performance_score": 10, "site": "yahoo.com", "participants_count": 2, "title_full": "InPlay from Briefing.com - Yahoo Finance", "spam_score": 0.0, "site_type": "news", "published": "2015-10-21T03:00:00.000+03:00", "replies_count": 10, "uuid": "160bf6726f7862d3ac123f8b917191913d4becd0"}, "author": "yahoo", "url": "http://finance.yahoo.com/news/inplay-briefing-com-055139997.html", "ord_in_thread": 0, "title": "InPlay from Briefing.com", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "5 Cool things you never knew about Elmer's Glue\nNow watching   Next video starts in : 7 Play \n5 Cool things you never knew about Elmer's Glue\n Replay video Up next IBM sales sink for 14th quarter \n   Up next   IBM sales sink for 14th quarter \nYahoo Finance: Business\n1\n 1:29 \nNow watching Up next 5 Cool things you never knew about Elmer's Glue \nA classic American company with an unexpected history.\n2\n 2:41 \nNow watching Up next IBM sales sink for 14th quarter \nWhat&#39;s going on at IBM?\n3\n 2:25 \nNow watching Up next Apple's early moves in music and TV looking up \nApple CEO Tim Cook was in high spirits on Monday, offering his vision on the future of music, television and automobiles.\n4\n 2:00 \nNow watching Up next How GM plans to beat Tesla \nThe giant automaker says battery breakthroughs for electric cars are happening faster than expected.\n5\n 4:24 \nNow watching Up next Tony Robbins: Pizza is key to retirement for millennials \nLove pizza? We&#39;ve got good news for you...\n6\n 1:06 \nNow watching Up next The most endangered presidential candidates \nNew fundraising data show half a dozen may have to drop out soon.\n7\n 2:54 \nNow watching Up next Goldman Sachs to report best quarter since financial crisis despite headwinds \nThis week we’ll get an important read on the Financials sector as 5 of the country’s biggest banks report Q3 results.\n8\n 4:24 \nNow watching Up next Tony Robbins on the importance of the 401k \nTony Robbins explains the intricate rules and importance of investing in your 401k\n9\n 2:16 \nNow watching Up next Weak market for First Data IPO could help investors \nThe stock market return of credit card processor First Data comes amid weak IPO performance. But that could be good for investors.\n10\n 2:25 \nNow watching Up next Twitter's football video removals raise questions for all media \nTwitter suspended the accounts of two prominent sports news sites over disputed use of short video clips.\nLoad More 3:47 am Credit Suisse misses by CHF0.09, misses on revs; proposes two share capital increases to further strengthen the Group's capital base ( CS ) : \nReports Q3 (Sep) earnings of $0.45 per share, $0.09 worse than the Capital IQ Consensus of $0.54; revenues fell 9.0% year/year to $5.99 bln vs the $6.42 bln Capital IQ Consensus. Reported Core pre-tax income of CHF 861 million Reported net income of CHF 779 million Both Private Banking & Wealth Management and Investment Banking results were impacted by low levels of client activity and adverse market conditions New assets: CHF 16.4 billion Additionally, co will propose to an Extraordinary General Meeting to be held on November 19, 2015, to approve two separate share capital increases: A first capital increase through the issuing of new registered shares to a number of qualified investors, and a second capital increase through a rights offering for existing shareholders. Through the proposed share capital increases, Credit Suisse Group AG intends to strengthen its Common Equity Tier 1 capital and gain greater financial flexibility for the implementation of its strategic objectives. 3:02 am Partner Comms to buy back Series B, C and E Notes ( PTNR ) : \nCo adopted a buy-back plan of Series B, C and E Notes, which are traded on the Tel Aviv Stock Exchange, according to which the Company may, from time to time, repurchase its Series B, C and E Notes. \nUnder the Plan, the Company is authorized to repurchase its Series B, C and E Notes up to an aggregate amount of NIS 250 million in open market transactions on the TASE, in privately negotiated transactions or in a combination of the two, until October 19, 2016. 2:58 am Novartis acquires Admune Therapeutics and licensing agreements with Palobiofarma and XOMA ( XOMA ) Corp ( NVS ) : \nNovartis announced today that it is broadening its portfolio of cancer immunotherapies with the acquisition of Admune Therapeutics and licensing agreements with Palobiofarma and XOMA ( XOMA ) Corporation. \nWith four programs currently in clinical trials and five more expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the body's immune system to combat cancers. Deals add IL-15, adenosine receptor and TGF-beta inhibition programs to Novartis immuno-oncology portfolio. All three programs will be explored as monotherapies and in combination with chimeric antigen receptor T-cell technology, novel checkpoint inhibitors, STING agonists and Novartis' deep portfolio of targeted therapies 2:49 am Synta Pharma terminates Phase 3 GALAXY-2 trial of ganetespib and docetaxel ( SNTA ) : \nCo announced it has decided to terminate the Phase 3 GALAXY-2 trial of ganetespib and docetaxel in the second-line treatment of patients with advanced non-small cell lung adenocarcinoma. Based on the review of a pre-planned interim analysis, the study's Independent Data Monitoring Committee concluded that the addition of ganetespib to docetaxel is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared to docetaxel alone . The IDMC noted that the combination of ganetespib and docetaxel was generally well tolerated in the study, with an adverse event profile consistent with previous studies combining these agents.\nUpon formal acceptance of the IDMC's recommendation, Synta will communicate with regulatory authorities, and will notify study investigators that treatment with ganetespib should be discontinued in the GALAXY-2 trial.\nCompany Earnings Credit Suisse", "external_links": [], "published": "2015-10-21T03:00:00.000+03:00", "crawled": "2015-10-21T11:14:54.728+03:00", "highlightTitle": ""}